MX384120B - Composiciones de vacuna. - Google Patents

Composiciones de vacuna.

Info

Publication number
MX384120B
MX384120B MX2016013299A MX2016013299A MX384120B MX 384120 B MX384120 B MX 384120B MX 2016013299 A MX2016013299 A MX 2016013299A MX 2016013299 A MX2016013299 A MX 2016013299A MX 384120 B MX384120 B MX 384120B
Authority
MX
Mexico
Prior art keywords
sub
alkyl
vaccine compositions
excipient
influenza antigen
Prior art date
Application number
MX2016013299A
Other languages
English (en)
Other versions
MX2016013299A (es
Inventor
Jeffrey Drew
Original Assignee
Stabilitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stabilitech Ltd filed Critical Stabilitech Ltd
Publication of MX2016013299A publication Critical patent/MX2016013299A/es
Publication of MX384120B publication Critical patent/MX384120B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de un excipiente que es un compuesto de la fórmula (I) o una de sus sales o ésteres fisiológicamente aceptables: en donde: R1 representa alquilo de C1-6; R2 representa hidrógeno o alquilo de C1-6; y R3 representa alquilo de C1-6, para el aumento de la inmunogenicidad de un antígeno de influenza, cuyo uso comprende (a) congelar, (b) tratar con calor, y/o (c) liofilizar una composición acuosa que comprende el antígeno de influenza y el excipiente.
MX2016013299A 2014-04-11 2015-04-08 Composiciones de vacuna. MX384120B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1406569.2A GB201406569D0 (en) 2014-04-11 2014-04-11 Vaccine compositions
PCT/GB2015/051072 WO2015155527A1 (en) 2014-04-11 2015-04-08 Vaccine compositions

Publications (2)

Publication Number Publication Date
MX2016013299A MX2016013299A (es) 2017-04-27
MX384120B true MX384120B (es) 2025-03-14

Family

ID=50844882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013299A MX384120B (es) 2014-04-11 2015-04-08 Composiciones de vacuna.

Country Status (14)

Country Link
US (2) US10086064B2 (es)
EP (1) EP3129007B1 (es)
JP (1) JP6745223B2 (es)
KR (1) KR102395712B1 (es)
CN (1) CN106456585B (es)
AU (1) AU2015245313B2 (es)
CA (1) CA2945201C (es)
DK (1) DK3129007T3 (es)
ES (1) ES2828174T3 (es)
GB (2) GB201406569D0 (es)
HU (1) HUE051528T2 (es)
IL (1) IL248223B (es)
MX (1) MX384120B (es)
WO (1) WO2015155527A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552478B1 (en) 2010-03-31 2016-12-21 Stabilitech Ltd. Excipients for stabilising viral particles
HUE026885T2 (en) 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3565591A1 (en) * 2017-01-06 2019-11-13 Stabilitech Biopharma Ltd Virus
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
KR20240018697A (ko) 2017-06-10 2024-02-13 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7630603B2 (ja) 2020-08-10 2025-02-17 インベントプライズ・インコーポレイテッド 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US4980277A (en) 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
JP3064413B2 (ja) 1989-08-15 2000-07-12 マサチユセツツ・インスチチユート・オブ・テクノロジー 安定化ワクチン組成物
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
RU2099418C1 (ru) 1991-11-21 1997-12-20 Лонца Аг Фрагмент днк, обеспечивающий использование бетаина, рекомбинантная плазмидная днк с фрагментом днк, обеспечивающим использование бетаина, штамм бактерий rhizobium/agrobacterium, предназначенный для стабильного хранения плазмиды с фрагментом днк, способ получения штамма бактерий
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
FR2698879B1 (fr) 1992-12-09 1995-01-13 Rhone Poulenc Biochimie gellules modifiées au niveau du catabolisme de la bétaïne, préparation et utilisations, notamment pour la production de métabolites ou d'enzymes.
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5965438A (en) 1995-06-07 1999-10-12 Phyton, Inc. Cryopreservation of plant cells
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US6037116A (en) 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
JP2001524306A (ja) 1997-11-26 2001-12-04 ユニバーサル プリザーベーション テクノロジーズ インコーポレイテッド ガラス化による不安定な生物学的サンプルの保存
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
WO2001093829A2 (en) 2000-06-08 2001-12-13 Powderject Vaccines, Inc. Powder compositions
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
US7229645B2 (en) 2001-06-08 2007-06-12 Powderject Research Limited Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP1466925B1 (en) 2001-12-28 2009-09-02 Kyowa Hakko Kirin Co., Ltd. Antibodies against fibroblast growth factor 23
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
JP2003261591A (ja) 2002-03-08 2003-09-19 Koji Hayade 凍結乾燥安定剤
AU2003240437A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
EP1523563A2 (en) 2002-07-10 2005-04-20 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
WO2004035818A1 (en) 2002-10-21 2004-04-29 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
US7462700B2 (en) 2002-12-10 2008-12-09 Schering-Plough Animal Health Corporation Canine RANKL and methods for preparing and using the same
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
NZ544011A (en) 2003-06-10 2009-02-28 Univ Melbourne Immunomodulating compositions uses therefor and processes for their production
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
WO2005062709A2 (en) 2003-12-30 2005-07-14 Virumar Pituach Tarkivim Ltd. Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
CN101060831B (zh) 2004-10-01 2010-06-23 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
DK1824460T3 (en) 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
AU2006207901A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
KR20160045151A (ko) 2005-04-08 2016-04-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
PT1954308E (pt) 2005-09-16 2011-11-03 Merial Ltd Estabilizadores para vacinas liofilizadas
RU2008117396A (ru) 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) Твердая вакцинная композиция
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
WO2007063903A1 (ja) 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
MX2008010562A (es) 2006-02-15 2009-03-05 Imclone Systems Inc Formulacion de anticuerpo.
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
ES2286951B1 (es) 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
US20090053197A1 (en) 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
WO2008058035A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
DK2829282T3 (en) 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
JP2010530846A (ja) 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
WO2009006097A1 (en) 2007-06-29 2009-01-08 Johnson & Johnson Regenerative Therapeutics, Llc Liquid protein formulations comprising gdf-5 for use at elevated temperatures
WO2009015343A2 (en) 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
CN102026619A (zh) 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
CN102164943A (zh) 2008-09-24 2011-08-24 稳定技术有限公司 使用糖和聚乙烯亚胺保存多肽的方法
WO2010146598A2 (en) 2008-11-07 2010-12-23 Serum Institute Of India Ltd. Stable, dried rotavirus vaccine, compositions and process for preparation thereof
CN101450209B (zh) 2008-12-31 2012-01-25 中国人民解放军军事医学科学院微生物流行病研究所 透皮免疫流感多价疫苗的制备及其方法
US8519125B2 (en) 2009-05-11 2013-08-27 Biomatrica, Inc. Compositions and methods for biological sample storage
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
HUE026885T2 (en) * 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
JP6023696B2 (ja) * 2010-03-31 2016-11-09 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
EP2552478B1 (en) 2010-03-31 2016-12-21 Stabilitech Ltd. Excipients for stabilising viral particles
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
GB201208293D0 (en) 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3565591A1 (en) 2017-01-06 2019-11-13 Stabilitech Biopharma Ltd Virus
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions

Also Published As

Publication number Publication date
US10086064B2 (en) 2018-10-02
US20170021008A1 (en) 2017-01-26
GB2539148A (en) 2016-12-07
JP2017510612A (ja) 2017-04-13
IL248223A0 (en) 2016-11-30
US20190000961A1 (en) 2019-01-03
DK3129007T3 (da) 2020-11-02
WO2015155527A1 (en) 2015-10-15
MX2016013299A (es) 2017-04-27
JP6745223B2 (ja) 2020-08-26
US10806783B2 (en) 2020-10-20
AU2015245313B2 (en) 2020-01-23
GB201617324D0 (en) 2016-11-23
IL248223B (en) 2021-01-31
CN106456585B (zh) 2022-08-16
CA2945201A1 (en) 2015-10-15
CA2945201C (en) 2022-08-16
AU2015245313A1 (en) 2016-11-03
KR102395712B1 (ko) 2022-05-09
HUE051528T2 (hu) 2021-03-01
CN106456585A (zh) 2017-02-22
KR20170032885A (ko) 2017-03-23
EP3129007B1 (en) 2020-07-29
ES2828174T3 (es) 2021-05-25
EP3129007A1 (en) 2017-02-15
GB201406569D0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
MX384120B (es) Composiciones de vacuna.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
WO2016007576A3 (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
EA201201321A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
PH12019501359A1 (en) Polymorphs
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
PH12019501362B1 (en) Polymorphs
MX376283B (es) Compuestos de imidazopiridazina.
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
MX373603B (es) Activador de canales de kcnq2-5.
PH12020550947A1 (en) Polymorphs
MX383032B (es) Formulaciones farmaceuticas inyectables de lefamulina.
MX2019012620A (es) Composiciones de vacunas.
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов